Cargando…

Pharmaceutical company payments to dermatology Clinical Practice Guideline authors in Japan

Clinical Practice Guidelines (CPGs) play significant roles in most medical fields. However, little is known about the extent of financial Conflicts of Interest (FCOIs) related to pharmaceutical companies (Pharma) selling dermatology prescription products and dermatology CPG authors in Japan. The aim...

Descripción completa

Detalles Bibliográficos
Autores principales:	Murayama, Anju, Ozaki, Akihiko, Saito, Hiroaki, Sawano, Toyoaki, Shimada, Yuki, Yamamoto, Kana, Suzuki, Yosuke, Tanimoto, Tetsuya
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7553305/ https://www.ncbi.nlm.nih.gov/pubmed/33048952 http://dx.doi.org/10.1371/journal.pone.0239610

Ejemplares similares

Payments From Pharmaceutical Companies to Authors Involved in the Valsartan Scandal in Japan
por: Sawano, Toyoaki, et al.
Publicado: (2019)

Pharmaceutical company payments to authors of the Japanese guidelines for the management of hypertension
por: Senoo, Yuki, et al.
Publicado: (2021)

Evaluation of Pharmaceutical Company Payments and Conflict of Interest Disclosures Among Oncology Clinical Practice Guideline Authors in Japan
por: Saito, Hiroaki, et al.
Publicado: (2019)

Pharmaceutical company payments to the authors of the Japanese dementia clinical practice guidelines in 2016
por: Shimada, Yuki, et al.
Publicado: (2019)

Pharmaceutical payments to Japanese certified hematologists: a retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
por: Kusumi, Eiji, et al.
Publicado: (2022)

Coronavirus disease 2019 experts appearing on Japanese television: their characteristics and financial conflicts of interest with pharmaceutical companies
por: Murayama, Anju, et al.
Publicado: (2021)

Pharmaceutical payments to certified oncology specialists in Japan in 2016: a retrospective observational cross-sectional analysis
por: Ozaki, Akihiko, et al.
Publicado: (2019)

How Do Institutional Conflicts of Interest Between Pharmaceutical Companies and the Healthcare Sector Become Corrupt? A Case Study of Scholarship Donations Between Department of Clinical Anesthesiology, Mie University, and Ono Pharmaceutical in Japan
por: Ozaki, Akihiko, et al.
Publicado: (2022)

Nature and Trends in Personal Payments Made to the Respiratory Physicians by Pharmaceutical Companies in Japan between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Pharmaceutical Payments to Japanese Board-Certified Infectious Disease Specialists: A Four-Year Retrospective Analysis of Payments from 92 Pharmaceutical Companies between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2022)

Pharmaceutical payments to Japanese board-certified dermatologists: a 4-year retrospective analysis of personal payments from pharmaceutical companies between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Pharmaceutical Payments to Japanese Board‐Certified Head and Neck Surgeons Between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Awareness and Perceptions among Members of a Japanese Cancer Patient Advocacy Group Concerning the Financial Relationships between the Pharmaceutical Industry and Physicians
por: Murayama, Anju, et al.
Publicado: (2022)

Cross-sectional analysis of pharmaceutical payments to Japanese board-certified gastroenterologists between 2016 and 2019
por: Murayama, Anju, et al.
Publicado: (2023)

Trends in Industry Payments to Diabetologists and Endocrinologists in the United States During the COVID-19 Pandemic
por: Murayama, Anju, et al.
Publicado: (2022)

Research and Nonresearch Industry Payments for COVID-19 mRNA Vaccines in the United States
por: Murayama, Anju, et al.
Publicado: (2023)

Trend in industry payments to infectious disease physicians in the United States: a seven-year analysis of nonresearch payments from the Open Payments Database between 2014 and 2020
por: Murayama, Anju, et al.
Publicado: (2022)

Industry payments to allergists and clinical immunologists in the United States during the coronavirus disease 2019 pandemic
por: Murayama, Anju, et al.
Publicado: (2022)

The Trend in Industry Payments During the COVID-19 Pandemic Among Gastroenterologists and Hepatologists in the United States
por: Murayama, Anju, et al.
Publicado: (2022)

Assessment of Financial Relationships Between Otorhinolaryngologists and Pharmaceutical Companies in Japan Between 2016 and 2019
por: Kamamoto, Sae, et al.
Publicado: (2023)

Will initial consultation patterns among undiagnosed cancer patients be the same after this COVID-19 pandemic? Experiences from the 2011 triple disaster in Fukushima, Japan
por: Ozaki, Akihiko, et al.
Publicado: (2020)

Are Pharmaceutical Company Payments Incentivising Malpractice in Japanese Physicians?
por: Kobashi, Yurie, et al.
Publicado: (2019)

Evaluation of financial conflicts of interest and drug statements in the coronavirus disease 2019 clinical practice guideline in Japan
por: Hashimoto, Takanao, et al.
Publicado: (2022)

Observational study of financial and non-financial conflicts of interest among the Japanese government advisory board members concerning coronavirus disease 2019
por: Mamada, Hanano, et al.
Publicado: (2023)

Nosocomial SARS-CoV-2 Infections in Japan: A Cross-sectional Newspaper Database Survey
por: Tani, Yuta, et al.
Publicado: (2020)

Underperformance of Reverse-Transcriptase Polymerase Chain Reaction in Japan and Potential Implications From Diamond Princess Cruise Ship and Other Countries During the Ongoing COVID-19 Pandemic
por: Yamamoto, Kana, et al.
Publicado: (2020)

Pharmaceutical Payments to Authors of Dermatology Guidelines After Publication
por: Sivesind, Torunn E, et al.
Publicado: (2022)

International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency
por: Ozieranski, Piotr, et al.
Publicado: (2023)

Limited capacity of SARS-CoV-2 variants testing in Japan: A secondary analysis using publicly available data
por: Hashimoto, Takanao, et al.
Publicado: (2021)

Error in Payments From Some Pharmaceutical Companies
Publicado: (2019)

Generic drug crisis in Japan and changes leading to the collapse of universal health insurance established in 1961: the case of Kobayashi Kako Co. Ltd.
por: Kosaka, Makoto, et al.
Publicado: (2023)

Social isolation and cancer management – advanced rectal cancer with patient delay following the 2011 triple disaster in Fukushima, Japan: a case report
por: Ozaki, Akihiko, et al.
Publicado: (2017)

Negative Aspects of the Regional Quota System in Japan
por: Yamamoto, Kana, et al.
Publicado: (2019)

Are the issues pointed out by ChatGPT can be applied to Japan? - Examining the reasons behind high COVID-19 excess deaths in Japan
por: Kaneda, Yudai, et al.
Publicado: (2023)

Industry Payments During the COVID-19 Pandemic to Cardiologists in the United States
por: Murayama, Anju, et al.
Publicado: (2023)

Physician Payments from Pharmaceutical Companies Related to Cancer Drugs
por: Mitchell, Aaron P, et al.
Publicado: (2022)

Japan’s Drug Regulation Framework: Aiming for Better Health or Bigger Profits?
por: Ozaki, Akihiko, et al.
Publicado: (2020)

Association between COVID-19 incidence and postponement or cancellation of elective surgeries in Japan until September 2020: a cross-sectional, web-based survey
por: Kurokawa, Tomohiro, et al.
Publicado: (2022)

The long term participation trend for the colorectal cancer screening after the 2011 triple disaster in Minamisoma City, Fukushima, Japan
por: Saito, Hiroaki, et al.
Publicado: (2021)

Interruption of breast cancer care and importance of inter‐hospital cooperation during the COVID‐19 pandemic: A case report of advanced breast cancer in Fukushima, Japan
por: Ozaki, Akihiko, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_4onf9od9i4rju3u3iia2vv4f1s